TENAYA and LUCERNE
Most Cited Paper
in Retinal Diseases and Treatments
18 Months Post-Publication
Class of 2026
“TENAYA and LUCERNE”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Faricimab · bispecific antibody · Angiopoietin-2 inhibition · VEGF-A inhibition · Neovascular age-related macular degeneration · aflibercept · Treat-and-extend regimen · personalized treatment interval · Best-corrected visual acuity · intravitreal injection · Every-16-week dosing · Treatment interval extension · Phase 3 clinical trial · Treatment-naïve patients · disease activity-based dosing · dual pathway inhibition
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459